Page last updated: 2024-11-05

thalidomide and Thyroid Neoplasms

thalidomide has been researched along with Thyroid Neoplasms in 11 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Thyroid Neoplasms: Tumors or cancer of the THYROID GLAND.

Research Excerpts

ExcerptRelevanceReference
"Since thyroid carcinomas are hypervascular and thalidomide is antiangiogenic, we assessed thalidomide's tumoristatic effects and toxicity in a phase II trial."2.73Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas. ( Ain, KB; Lee, C; Williams, KD, 2007)
"The incidence of thyroid cancer continues to increase and this neoplasia remains the most common endocrine malignancy."2.48Novel molecular targeted therapies for refractory thyroid cancer. ( Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES, 2012)
"Thalidomide has no effect on tumor growth, but is also associated with increased VEGF and p53 expression."1.31Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice. ( Bauer, AJ; Doniparthi, NK; Francis, GL; Patel, A; Ringel, MD; Saji, M; Terrell, R; Tuttle, RM, 2002)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (36.36)29.6817
2010's6 (54.55)24.3611
2020's1 (9.09)2.80

Authors

AuthorsStudies
He, L1
Chen, C1
Gao, G1
Xu, K1
Ma, Z1
Winiczenko, R1
Górnicki, K1
Kaleta, A1
Janaszek-Mańkowska, M1
Khan, ZA1
Singh, C1
Khan, T1
Ganguly, M1
Bradsher, C1
Goodwin, P1
Petty, JT1
Sandau, C1
Bove, DG1
Marsaa, K1
Bekkelund, CS1
Lindholm, MG1
Salazar, J1
Bermúdez, V1
Olivar, LC1
Torres, W1
Palmar, J1
Añez, R1
Ordoñez, MG1
Rivas, JR1
Martínez, MS1
Hernández, JD1
Graterol, M1
Rojas, J1
Mubarak, Z1
Humaira, A1
Gani, BA1
Muchlisin, ZA1
Gremillet, C1
Jakobsson, JG1
Gomila, A1
Shaw, E1
Carratalà, J1
Leibovici, L1
Tebé, C1
Wiegand, I1
Vallejo-Torres, L1
Vigo, JM1
Morris, S1
Stoddart, M1
Grier, S1
Vank, C1
Cuperus, N1
Van den Heuvel, L1
Eliakim-Raz, N1
Vuong, C1
MacGowan, A1
Addy, I1
Pujol, M1
Cobb, A1
Rieger, E1
Bell, J1
Mallik, S1
Zhao, Z1
Szécsényi, Á1
Li, G1
Gascon, J1
Pidko, EA1
Zhang, GR1
Wolker, T1
Sandbeck, DJS1
Munoz, M1
Mayrhofer, KJJ1
Cherevko, S1
Etzold, BJM1
Lukashuk, L1
Yigit, N1
Rameshan, R1
Kolar, E1
Teschner, D1
Hävecker, M1
Knop-Gericke, A1
Schlögl, R1
Föttinger, K1
Rupprechter, G1
Franconieri, F1
Deshayes, S1
de Boysson, H1
Trad, S1
Martin Silva, N1
Terrier, B2
Bienvenu, B1
Galateau-Sallé, F1
Emile, JF1
Johnson, AC1
Aouba, A2
Vogt, TJ1
Gevensleben, H1
Dietrich, J1
Kristiansen, G1
Bootz, F1
Landsberg, J1
Goltz, D1
Dietrich, D1
Idorn, M1
Skadborg, SK1
Kellermann, L1
Halldórsdóttir, HR1
Holmen Olofsson, G1
Met, Ö1
Thor Straten, P1
Johnson, LE1
Brockstedt, D1
Leong, M1
Lauer, P1
Theisen, E1
Sauer, JD1
McNeel, DG1
Morandi, F1
Marimpietri, D1
Horenstein, AL1
Bolzoni, M1
Toscani, D1
Costa, F1
Castella, B1
Faini, AC1
Massaia, M1
Pistoia, V1
Giuliani, N1
Malavasi, F1
Qiu, J1
Peng, S1
Yang, A1
Ma, Y1
Han, L1
Cheng, MA1
Farmer, E1
Hung, CF1
Wu, TC1
Modak, S1
Le Luduec, JB1
Cheung, IY1
Goldman, DA1
Ostrovnaya, I1
Doubrovina, E1
Basu, E1
Kushner, BH1
Kramer, K1
Roberts, SS1
O'Reilly, RJ1
Cheung, NV1
Hsu, KC1
Salgarello, T1
Giudiceandrea, A1
Calandriello, L1
Marangoni, D1
Colotto, A1
Caporossi, A1
Falsini, B1
Lefrançois, P1
Xie, P1
Wang, L2
Tetzlaff, MT1
Moreau, L1
Watters, AK1
Netchiporouk, E1
Provost, N1
Gilbert, M1
Ni, X1
Sasseville, D1
Wheeler, DA1
Duvic, M1
Litvinov, IV1
O'Connor, BJ1
Fryda, NJ1
Ranglack, DH1
Yang, Y2
Yang, J1
Zhang, X2
Grün, AL1
Emmerling, C1
Aumeeruddy-Elalfi, Z1
Ismaël, IS1
Hosenally, M1
Zengin, G1
Mahomoodally, MF1
Dotsenko, A1
Gusakov, A1
Rozhkova, A1
Sinitsyna, O1
Shashkov, I1
Sinitsyn, A1
Hong, CE1
Kim, JU1
Lee, JW1
Lee, SW1
Jo, IH1
Pandiyarajan, S1
Premasudha, P1
Kadirvelu, K1
Wang, B1
Luo, L1
Wang, D1
Ding, R1
Hong, J1
Caviezel, D1
Maissen, S1
Niess, JH1
Kiss, C1
Hruz, P1
Pockes, S1
Wifling, D1
Keller, M1
Buschauer, A1
Elz, S1
Santos, AF1
Ferreira, IP1
Pinheiro, CB1
Santos, VG1
Lopes, MTP1
Teixeira, LR1
Rocha, WR1
Rodrigues, GLS1
Beraldo, H1
Lohar, S1
Dhara, K1
Roy, P1
Sinha Babu, SP1
Chattopadhyay, P1
Sukwong, P1
Sunwoo, IY1
Lee, MJ1
Ra, CH1
Jeong, GT1
Kim, SK2
Huvinen, E1
Eriksson, JG1
Stach-Lempinen, B1
Tiitinen, A1
Koivusalo, SB1
Malhotra, M1
Suresh, S1
Garg, A1
Wei, L1
Jiang, Y2
Zhou, W1
Liu, S1
Liu, Y1
Rausch-Fan, X1
Liu, Z1
Marques, WL1
van der Woude, LN1
Luttik, MAH1
van den Broek, M1
Nijenhuis, JM1
Pronk, JT1
van Maris, AJA1
Mans, R1
Gombert, AK1
Xu, A1
Sun, J1
Li, J1
Chen, W2
Zheng, R1
Han, Z1
Ji, L1
Shen, WQ1
Bao, LP1
Hu, SF1
Gao, XJ1
Xie, YP1
Gao, XF1
Huang, WH1
Lu, X1
Gostin, PF1
Addison, O1
Morrell, AP1
Zhang, Y2
Cook, AJMC1
Liens, A1
Stoica, M1
Ignatyev, K1
Street, SR1
Wu, J1
Chiu, YL1
Davenport, AJ1
Qiu, Z1
Shu, J1
Tang, D1
Gao, X1
Zhang, J3
Huang, K1
Wai, H1
Du, K1
Anesini, J1
Kim, WS1
Eastman, A1
Micalizio, GC1
Liang, JH1
Huo, XK1
Cheng, ZB1
Sun, CP1
Zhao, JC1
Kang, XH1
Zhang, TY1
Chen, ZJ1
Yang, TM1
Wu, YY1
Deng, XP1
Zhang, YX1
Salem, HF1
Kharshoum, RM1
Abou-Taleb, HA1
AbouTaleb, HA1
AbouElhassan, KM1
Ohata, C1
Ohyama, B1
Kuwahara, F1
Katayama, E1
Nakama, T1
Kobayashi, S1
Kashiwagi, T1
Kimura, J1
Lin, JD1
Liou, MJ1
Hsu, HL1
Leong, KK1
Chen, YT1
Wang, YR1
Hung, WS1
Lee, HY1
Tsai, HJ1
Tseng, CP1
Alten, B1
Yesiltepe, M1
Bayraktar, E1
Tas, ST1
Gocmen, AY1
Kursungoz, C1
Martinez, A1
Sara, Y1
Huang, S2
Adams, E1
Van Schepdael, A1
Wang, Q1
Chung, CY1
Yang, W1
Yang, G1
Chough, S1
Chen, Y1
Yin, B1
Bhattacharya, R1
Hu, Y1
Saeui, CT1
Yarema, KJ1
Betenbaugh, MJ1
Zhang, H1
Patik, JC1
Tucker, WJ1
Curtis, BM1
Nelson, MD1
Nasirian, A1
Park, S1
Brothers, RM1
Dohlmann, TL1
Hindsø, M1
Dela, F1
Helge, JW1
Larsen, S1
Gayani, B1
Dilhari, A1
Wijesinghe, GK1
Kumarage, S1
Abayaweera, G1
Samarakoon, SR1
Perera, IC1
Kottegoda, N1
Weerasekera, MM1
Nardi, MV1
Timpel, M1
Ligorio, G1
Zorn Morales, N1
Chiappini, A1
Toccoli, T1
Verucchi, R1
Ceccato, R1
Pasquali, L1
List-Kratochvil, EJW1
Quaranta, A1
Dirè, S1
Heo, K1
Jo, SH1
Shim, J1
Kang, DH1
Kim, JH1
Park, JH1
Akhtar, N1
Saha, A1
Kumar, V1
Pradhan, N1
Panda, S1
Morla, S1
Kumar, S1
Manna, D1
Wang, H1
Xu, E1
Yu, S1
Li, D1
Quan, J1
Xu, L1
Saslow, SA1
Um, W1
Pearce, CI1
Bowden, ME1
Engelhard, MH1
Lukens, WL1
Kim, DS1
Schweiger, MJ1
Kruger, AA1
Adair, LS1
Kuzawa, C1
McDade, T1
Carba, DB1
Borja, JB1
Liang, X2
Song, W1
Wang, K1
Zhang, B1
Peele, ME1
Luo, HR1
Chen, ZY1
Fei, JJ1
Du, ZJ1
Yi, KJ1
Im, WT1
Kim, DW1
Ji, X1
Zhang, C1
Xu, Z1
Ding, Y1
Song, Q1
Li, B2
Zhao, H1
Lee, DW1
Lee, H1
Kwon, BO1
Khim, JS1
Yim, UH1
Park, H1
Park, B1
Choi, IG1
Kim, BS1
Kim, JJ1
Wang, JJ1
Chen, Q1
Li, YZ1
Sakai, M1
Yamaguchi, M1
Nagao, Y1
Kawachi, N1
Kikuchi, M1
Torikai, K1
Kamiya, T1
Takeda, S1
Watanabe, S1
Takahashi, T1
Arakawa, K1
Nakano, T1
Rufo, S1
Continentino, MA1
Nikolaou, V1
Plass, F1
Planchat, A1
Charisiadis, A1
Charalambidis, G1
Angaridis, PA1
Kahnt, A1
Odobel, F1
Coutsolelos, AG1
Fuentes, I1
García-Mendiola, T1
Sato, S1
Pita, M1
Nakamura, H1
Lorenzo, E1
Teixidor, F1
Marques, F1
Viñas, C1
Liu, F1
Qi, P1
Zhang, L1
van Rhee, F1
Stone, K1
Mohammed, AA1
El-Shentenawy, A1
Mizutani, S1
Kuroda, J1
Sasaki, N1
Kiyota, M1
Tatekawa, S1
Tsukamoto, T1
Maegawa, S1
Chinen, Y1
Shimura, Y1
Nagoshi, H1
Kobayashi, T1
Horiike, S1
Tando, S1
Fushiki, S1
Taniwaki, M1
Grushka, JR1
Ryckman, J1
Mueller, C1
Roessingh, Ade B1
Walton, JM1
St Vil, D1
Laberge, JM1
Bernard, C1
Nguyen, VH1
Puligandla, PS1
Kraeber-Bodéré, F1
Bodet-Milin, C1
Niaudet, C1
Saï-Maurel, C1
Moreau, A1
Faivre-Chauvet, A1
Thomare, P1
Deleris, G1
Estieu-Gionnet, K1
Bikfalvi, A1
Barbet, J1
Paris, F1
Perez, CA1
Santos, ES1
Arango, BA1
Raez, LE1
Cohen, EE1
Bauer, AJ1
Terrell, R1
Doniparthi, NK1
Patel, A1
Tuttle, RM1
Saji, M1
Ringel, MD1
Francis, GL1
Diop, S1
Clerc, J1
Vasiliu, V1
Munera, Y1
Hermine, O1
Ain, KB1
Lee, C1
Williams, KD1

Reviews

3 reviews available for thalidomide and Thyroid Neoplasms

ArticleYear
Advanced thyroid cancers: new era of treatment.
    Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:7

    Topics: Anilides; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; Cell Proliferation

2014
Spindle epithelial tumor with thymus-like elements of the thyroid: a multi-institutional case series and review of the literature.
    Journal of pediatric surgery, 2009, Volume: 44, Issue:5

    Topics: Abscess; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Celecoxib; Ch

2009
Novel molecular targeted therapies for refractory thyroid cancer.
    Head & neck, 2012, Volume: 34, Issue:5

    Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; B

2012

Trials

2 trials available for thalidomide and Thyroid Neoplasms

ArticleYear
    Neural computing & applications, 2018, Volume: 30, Issue:6

    Topics: Activities of Daily Living; Acute Disease; Adalimumab; Adaptation, Physiological; Adenosine Triphosp

2018
Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas.
    Thyroid : official journal of the American Thyroid Association, 2007, Volume: 17, Issue:7

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression;

2007

Other Studies

6 other studies available for thalidomide and Thyroid Neoplasms

ArticleYear
ARV-825-induced BRD4 protein degradation as a therapy for thyroid carcinoma.
    Aging, 2020, 03-12, Volume: 12, Issue:5

    Topics: Apoptosis; Azepines; bcl-X Protein; Carcinoma; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement;

2020
Storming the Castle with TCP.
    Blood, 2019, 04-18, Volume: 133, Issue:16

    Topics: Castleman Disease; Cyclophosphamide; Humans; Prednisone; Thalidomide; Thyroid Neoplasms

2019
Quadruple Cancers of Non-producing Multiple Myeloma, Cholangiocellular Carcinoma, and Two Different Thyroid Cancers.
    Internal medicine (Tokyo, Japan), 2016, Volume: 55, Issue:9

    Topics: Aged; Bile Duct Neoplasms; Bortezomib; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; C

2016
Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2010, Volume: 51, Issue:4

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Apoptosis; Carcinoembryonic Antigen; Cell

2010
Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice.
    Thyroid : official journal of the American Thyroid Association, 2002, Volume: 12, Issue:11

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Body Weight; Carcinoma; Cell Division; End

2002
Thyroid gland plasmacytoma with a dramatic and persistent complete response under thalidomide and dexamethasone-associated treatment.
    Leukemia & lymphoma, 2006, Volume: 47, Issue:7

    Topics: Aged; Antineoplastic Agents, Hormonal; Dexamethasone; Female; Humans; Immunosuppressive Agents; Mult

2006